IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The goal of this first-in-human, single-center, prospective, open-label, phase 1/2 trial is
to evaluate the safety and efficacy of the interferon alpha expressing mesenchymal stromal
cells (MSC-IFNα) combined with or without immunochemotherapy in patients with locally
advanced/metastatic solid tumors. The main questions aimed to answer are 1) to evaluate the
safety and feasibility of MSC-IFNα in the treatment of locally advanced/metastatic solid
tumors;2) to evaluate the anti-tumor effects of the MSC-IFNα combined with or without
immunochemotherapy in the treatment of locally advanced/metastatic solid tumors; 3) to
evaluate the pharmacokinetics/pharmacodynamics of MSC-IFNα and related immune effector cells.